Navigation Links
Drug could reverse scourge of cerebral malaria for survivors
Date:5/1/2012

ncet Neurology.

The new clinical trial will test the safety and feasibility of LVT to control seizures in children specifically with cerebral malaria. Instead of delivering the drug intravenously, which is too costly for most developing nations such as Malawi, it will be given via a tube in the nasal passage, an effective method in hospitals and clinics that lack resources.

About 40 children will be selected for the trial. If all safety standards are met, dosage will be increased until 75 percent of children are free of seizures for 24 hours (typically, only 20 percent of children admitted with cerebral malaria and seizures are seizure free in the first 24 hours).

To accurately test whether children are staying seizure free, MSU is collaborating with New York-based biotechnology firm Bio-Signal Group, which has created a portable, wireless EEG monitoring device, called microEEG that can accommodate up to 32 electrodes and connects via Bluetooth technology to a small monitoring machine.

"Unfortunately, many children who survive malaria continue to have seizures with no physical symptoms, but their brains still are being damaged," Birbeck said. "To evaluate the effectiveness of LVT, we need continuous EEG monitoring, which is very tough to do even in the best environment."

Bio-Signal's microEEG features a monitor the size of a deck of cards that can be worn on the arm, with a collection of wires going to the electrodes on the child's head. The monitor then transfers data in real-time to a computer, where it quickly can be analyzed and shared with colleagues.

"This state-of-the-art technology, which we believe can be used effectively in our resource-limited setting, allows us to conduct this trial," Birbeck said.

If the clinical trial shows LVT can be safe and potentially effective for seizure control in cerebral malaria, Birbeck and her team will proceed with a phase III randomized clinical trial.
'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Vitiligo skin disorder could yield clues in fight against melanoma
2. Saliva proteins could help detection of oral cancer
3. Research about plant viruses could lead to new ways to improve crop yields
4. Nanodiamond drug device could transform cancer treatment
5. UNC study on properties of carbon nanotubes, water could have wide-ranging implications
6. So-called sandfish could help materials handling and process technology specialists
7. Discovery of natural compounds that could slow blood vessel growth
8. Researchers design artificial cells that could power medical implants
9. Herbicide-resistant grape could revitalize Midwest wine industry
10. Sensitive laser instrument could aid search for life on Mars
11. Could Dr. House be replaced by a computer?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug could reverse scourge of cerebral malaria for survivors
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
(Date:1/22/2015)... 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics ... its new website design. "When we launched FindBiometrics ... Peter O,Neill , founder and CEO of FindBiometrics. "Now ... involvement from the key players on a very broad scale.  ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... Studies on genetically engineered mice show that social stress ... atherosclerosis. Commonly used drugs to reduce blood pressure, however, ... a thesis presented at the University of Gothenburg, Sweden. ... is a correlation between psychosocial stress and the risk ...
... heart defects has been identified by a team of scientists, ... to new treatments for those affected by the conditions brought ... on identifying and studying the gene in zebrafish embryos, and ... studying the genetics of mice and people. "This ...
... 6, 2010 Parascript, LLC, the image analysis ... its Signature Xpert was awarded best performance ... Conference on Frontiers in Handwriting Recognition (ICFHR2010) in ... Parascript was among seven participants representing a total ...
Cached Biology News:Social stress leads to atherosclerosis 2Scientists find gene linked to congenital heart defect 2Scientists find gene linked to congenital heart defect 3Scientists find gene linked to congenital heart defect 4Parascript SignatureXpert Wins Forensic Signature Verification Competition 2
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  23andMe, ... of Kate Black as Privacy Officer and ... federal, and state privacy laws as well as health ... regulatory team, she will be responsible for reviewing, updating ... customers in the U.S. and abroad. She joined the ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... Human Genome Sciences, Inc. (Nasdaq: ... a conference call to discuss the results of its ... in patients with genotype 1 chronic hepatitis C.(Logo: ... senior management and will be held on Monday, March ...
... Corporation (Nasdaq: MNKD ) today announced that ... PFE ) to purchase Pfizer,s insulin facility ... related to the production of bulk insulin, including the ... of bulk insulin and a license to manufacture bulk ...
... ExonHit Therapeutics (Alternext:,ALEHT) today announced that 1,076,923 out ... November 8, 2011 have been converted,into shares. , ... 17,231 capital increase and EUR,6,982,769 increase in additional paid-in ... reduced to EUR 6,522,178 compared to EUR 13,522,178,as of ...
Cached Biology Technology:Human Genome Sciences to Sponsor Conference Call 2MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 2MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 3MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 4ExonHit Therapeutics Shareholders' Equity Strengthened by Exercise of More Than Half of its Convertible Bonds 2
1M stock solution (238mg/ml)...
Request Info...
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
Biology Products: